Immunization funding across 28 European countries.

Europe national immunization program vaccination funding vaccination policies vaccination/immunization

Journal

Expert review of vaccines
ISSN: 1744-8395
Titre abrégé: Expert Rev Vaccines
Pays: England
ID NLM: 101155475

Informations de publication

Date de publication:
06 2021
Historique:
pubmed: 25 3 2021
medline: 10 9 2021
entrez: 24 3 2021
Statut: ppublish

Résumé

Disease prevention and improving vaccination coverage in Europe are key elements contributing to resilient health systems and ensuring better health outcomes for all. The aim of this study was to describe the immunization funding landscape across all European Union 28 countries (EU28). Data collected in a targeted literature review supported descriptive analysis on the different indicators that were looked at: vaccines included in the EU28 national immunization programs (NIP), national immunization funding, immunization funding per capita (2015-2019) and percentage of health-care budget allocated to immunization. Immunization funding represents a small proportion of total healthcare spend in Europe (median 0.3%). In the context of the current COVID-19 pandemic, demographic changes, and the potential introduction of new vaccines; the need for adequate financing of immunization programs will be important, to establish resilient immunization systems and provide sustainable protection of the population against vaccine-preventable diseases. PLAIN LANGUAGE SUMMARY

Autres résumés

Type: plain-language-summary (eng)
PLAIN LANGUAGE SUMMARY

Identifiants

pubmed: 33759675
doi: 10.1080/14760584.2021.1905257
doi:

Substances chimiques

Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

639-647

Auteurs

Pascaline Faivre (P)

Market Access Vaccines, MSD, Lyon, France.

Goran Benčina (G)

Center for Observational and Real-world Evidence, MSD, Madrid, Spain.

Rosanne Campbell (R)

Syneos Health Consulting, Value Access & HEOR, London, UK.

Sibilia Quilici (S)

Public Policy, MSD, Brussels, Belgium.

Nicolas Dauby (N)

Department of Infectious Diseases, CHU Saint-Pierre, Brussels, Belgium; Institute for Medical Immunology, Université Libre De Bruxelles (ULB), Belgium; Environmental Health Research Centre, Public Health School, Université Libre De Bruxelles (ULB), Brussels, Belgium.

Goran Tešović (G)

Pediatric Infectious Diseases Department, University of Zagreb School of Medicine, Zagreb, Croatia.

Paolo Bonanni (P)

Department of Health Sciences, University of Florence, Florence, Italy.

Rosybel Drury (R)

Global Vaccines Medical & Scientific Affairs, MSD, Lyon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH